Graphite Bio’s $150-Million Series B Financing

Brown Rudnick LLP advised the lead investors RA Capital Management and Rock Springs Capital Management on the deal.

RA Capital Management and Rock Springs Capital Management acted as lead investors on the investment in Graphite Bio, a next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases. The $150-million Series B financing will allow Graphite Bio to advance into the clinic its pipeline of investigational high efficiency, targeted gene integration therapies with curative potential for serious diseases.

RA Capital and Rock Springs Capital led the financing with significant participation from new investors Cormorant Asset Management, Deerfield Management Company, Federated Hermes Kaufmann Funds, Fidelity Management & Research Company, Janus Henderson Investors, Logos Capital, OrbiMed, Perceptive Advisors, Surveyor Capital (a Citadel company), and Venrock Healthcare Capital Partners, joining existing investor Samsara BioCapital and founding investor Versant Ventures. RA Capital is a leading investment manager dedicated to evidence-based investing in public and private healthcare and life science companies developing drugs, medical devices, and diagnostics. Rock Springs Capital is a prominent private investment firm specializing in the healthcare and biotechnology sectors.

The Brown Rudnick deal team included Michael Cohen (Picture), Adam Schoen, and Robert Ruh.

Involved fees earner: Michael Cohen – Brown Rudnick; Robert Ruh III – Brown Rudnick; Adam Schoen – Brown Rudnick;

Law Firms: Brown Rudnick;

Clients: RA Capital Management; Rock Springs Capital;

Author: Martina Bellini